Presented by Dr Thomas Scullion this webinar focuses on using NHPs for the preclinical assessment of immunotherapy toxicity. Explore how clinical trials are de-risked by evaluating immuno-safety early in drug discovery, and how to incorporate exploratory toxicology NHP studies into your preclinical programs.

Presented by Dr Rajendra Kumari this webinar will discuss the drug discovery applications of HUB tumor organoids including large scale drug screening, in vivo model selection, and in silico drug discovery. She'll also explore how to improve predictivity in drug development with our unique matched in vitro PDXO/in vivo PDX pairs.

Review our latest oncology and immuno-oncology posters including tumor organoids for drug discovery and I/O drug development, orthotopic syngeneic models, and immunoprofiling data.

Review the breakthrough discoveries leading to the development of HUB Organoids. Explore the key features of these 3D in vitro models including organ morphology recapitulation, stability, genomic superiority, and long-term culture, as well as their main utilities in research and development.

Presented by Dr Rajendra Kumari this webinar explores how to overcome translational challenges in CAR-T cell therapy development. Learn more on the different preclinical models available for CAR-T and cell therapy efficacy and safety assessment including PDX, as well as a novel rare cell analysis platform for sensitive CAR-T detection.

Presented by Dr Fred Beasley this webinar explores how to select the most appropriate models for your preclinical obesity studies, including polygenic vs monogenic models and recommendations based on drug modes of action. We also review best practice in obesity study design to maximize data outcomes.

Presented by Dr Sylvia Boj, Hubrecht Organoid Technology this webinar reviews the development and application of HUB Organoids. Explore the many advantages of HUB Organoids within 3D in vitro modeling, including direct clinical relevance and immuno-oncology applications.

Learn more about NHPs as a valuable early-stage preclinical platform for non-GLP exploratory toxicology studies. Explore the robust data these studies generate in a rapid, flexible, and cost-effective manner to assess immunotherapy safety and de-risk future clinical trials.

Explore the key features of commonly used preclinical IBD models, including model development and example treatment studies. Learn how to choose the most appropriate model for your drug development program, based on drug target and mechanism of action alongside model disease pathogenesis and clinical relevance.